CDH1 and breast cancer: Collectively, the clearly improved consistency in BC subtyping and the increased frequency of CDH1 mutations in those BCs that were classified as ILC, as shown in the present study, may serve as strong arguments to recommend E‐cadherin as an obligate IHC marker to be assessed in every newly diagnosed BC.